TNFA and TNFB polymorphisms in myasthenia gravis

Archives of Neurology

Volumn 56, Issue 4, 1999, Pages 457-461

  Skeie, Geir O ^a,c   Pandey, Janardan P ^b   Aarli, Johan A ^a,b   Gilhus, Nils E ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CONNECTIN; LYMPHOTOXIN; PREDNISONE; RYANODINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; THYMOMA;

EID: 0032895494     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.4.457     Document Type: Article

References (36)

1. Lindstrom J, Shelton D, Fujii Y. Myasthenia gravis. Adv Immunol. 1988;42: 233-284.
2. Murphy J, Murphy SF. Myasthenia gravis in identical twins. Neurology. 1986; 36:78-80.
3. Bergoffen J, Zmijewski CM, Fischbeck KH. Familial autoimmune myasthenia gravis. Neurology. 1994;44(pt 1):551-554.
4. Degli-Esposti MA, Andreas A, Christiansen FT, Schalke B, Albert E, Dawkins RL An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes. Immunogenetics. 1992:35:355-364.
5. Marshall B, Leelayuwat C, Abraham LJ, Pinelli M, Dawkins RL. Large transcripts and sequence from a polymorphic 170 kb MHC region implicated in susceptibility to autoimmune disease. Immunogenetics. 1994;39:15-20.
6. Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D, Strominger JL Genes for tumor necrosis factor a and are linked to the human major histocompatibility complex. Proc tJatlAcadSci US A. 1986:83:8699-8702.
7. Galbraith GMP, Pandey JP. Tumor necrosis factor a (TNF-a) gene polymorphism in alopecia areata. Hum Genet. 1995:96:433-436.
8. Bouma G, Crusius JBA, Oudkerk Pool M, et al. Secretion of tumour necrosis factor a and lymphotoxin a in relation to polymorphisms in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel disease. Scand J Immunol. 1996;43: 456-463.
9. Huizinga TWJ, Westendorp RG, Bollen EL, et al. TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol. 1997:72:149-153.
10. Ahlberg RE, Pirskanen R, Lefvert AK. Defective T lymphocyte function in non-thymectomized patients with myasthenia gravis. Clin Immunol Immunopathol. 1991:60:93-105.
11. Matusevicius D, Navikas V, Palasik W, Pirskanen R, Fredrikson S, Link H. Tumor necrosis factor-a, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perform mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J Neuroimmunol. 1996:71:191-198.
12. D'Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TUFA promotor region. Immunogenetics. 1994:39:150-154.
13. Wilson AG, di Giovine FS, Blakemore AIF, Duff GW. Single base polymorphism in the human tumour necrosis factor a (TNF-a) gene detectable by Ned restriction of PCR product. Hum Mol Genet. 1992:1:353.
14. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LEA, Duff GW. An allelic polymorphism within the human tumor necrosis factor a promotor region is strongly associated with HLAA1, B8 and DR3 alleles. J Exp Med. 1993; 177:557-560.
15. Abraham LJ, Du DC, Zahedi K, Dawkins RL, Whitehead AS. Haplotypic polymorphism of the TNF-β gene. Immunogenetics. 1991:33:50-53.
16. Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an Afcol polymorphism in the first intron of the human TNF-β gene correlates with a variant amino acid in position 26 and a reduced level of TNF-β production. J Exp Med. 1991;173:209-219.
17. Mygland A, Aarli JA, Matre R, Gilhus ME. Ryanodine receptor antibodies related to severity of thymoma-associated myasthenia gravis. JNeurolNeurosurg Psychiatry. 1994:57:843-846.
18. Lefvert AK, Bergstrom K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry. 1978;41:394-403.
19. Gautel M, Lakey A, Barlow DP, et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology. 1993:43:1581-1585.
20. Mygland A, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol. 1992:32:589-591.
21. Ishihara M, Ohno S, Ishida T, et al. Genetic polymorphisms of the TNFB and HSP70 genes located in the human major histocompatibility complex in sarcoidosis. Tis-sue Antigens. 1995:46:59-62.
22. Spurkland A, Gilhus NE, Ronningen KS, Aarli JA, Vartdal F. Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Antigens. 1991:37:90-93.
23. Gilhus NE, Pandey JP, Gaarder PI, Aarli JA. Immunoglobulin allotypes in myasthenia gravis patients with a thymoma. J Autoimmun. 1990:3:299-305.
24. Skeie GO, Pandey JP, Aarli JA, Gilhus NE. Autoimmunity to ryanodine receptor and titin in myasthenia gravis is associated with GM allotypes. Autoimmunity. 1997:26:111-116.
25. Raknes G, Skeie GO, Gilhus NE, Aadland S, Vedeler C. FcγRIIA and FcγRIIIB polymorphisms in myasthenia gravis. J Neuroimmunol. 1998:81:173-176.
26. Hjelmstram P, Peacock P, Giscombe R, et al. Myasthenia gravis with thymic hyperplasia is associated with polymorphisms in the tumor necrosis factor region. Ann N Y Acad Sci. 1998:841:368-370.
27. Kehrl JH, Alvarez-Mon M, Delsing GA, Fauci AS. Lymphotoxin is an important T cell-derived growth factor for human B cells. Science. 1987:238:1144-1146.
28. Kehrl JH, Miller A, Fauci AS. Effect of tumor necrosis factor-a on mitogenactivated human B cells. JExp Med. 1987:166:786-791.
29. Conen-Kaminsky S, Devergne O, Delattre RM, et al. lnterleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia. Eur Cytokine Nehv. 1993:4:121-132.
30. McHugh SM, Rowland TL. Thalidomide and derivatives: immunological investigations of tumor necrosis factor-α (TNF-α) inhibition suggests drugs capable of selective gene regulation. Clin Exp Immunol. 1997:110:151-154.
31. Willcox N. Myasthenia gravis. Curr Opin Immunol. 1993:5:910-917.
32. Mygland A, Kuwajima G, Mikoshiba K, Tysnes OB, Aarli JA, Gilhus NE. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol. 1995; 62:79-83.
33. Pescarmona E, Rosati S, Pisacane A, Rendina EA, Venuta F, Baroni CD. Microscopic thymoma: histological evidence of multifocal cortical and medullary origin. Histopathology. 1992:20:263-266.
34. Puglisi F, Finato N, Marchini C, Floretti G, Beltrami CA. Microscopic thymoma and myasthenia gravis. J Clin Pathol. 1995:48:682-683.
35. Schneeberger A, Koszik F, Stingl G. Immunologie host defense in melanoma: delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. J Invest Dermatol. 1995;105(suppl):110S-116S.
36. Ollert MW, David K, Schmitt C, et al. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sei US A. 1996;93:4493-4503.